Amorfix Life Sciences Ltd., a theranostics company, engages in the development of therapeutic products and diagnostic devices for misfolded protein diseases. It develops therapeutic products to target and neutralize only the misfolded conformation of a given protein; diagnostic kits to detect low concentrations of misfolded aggregated proteins in a diseased patient sample, as well as offers diagnostic services to Alzheimer's researchers and prion removal equipment manufacturers; and custom assay development services. The company's diagnostic programs include EP-AD CSF Diagnostic Test, an assay for the detection of the aggregated form of Aβ in human cerebrospinal fluid (CSF); blood test for use as a diagnostic tool for amyotrophic lateral sclerosis; and liver cancer screening assay. It develops therapeutic products comprising antibodies and vaccines for the treatment of amyotrophic lateral sclerosis and cancer. The company also produces reagents, including antibodies for detecting the human amyloid beta peptide and the prion protein; and Peroxynitrite, an oxidizing agent for various research applications. It has a collaboration agreement with Helix BioPharma to produce antibody-urease conjugates. The company is headquartered in Mississauga, Canada.

Key Statistics